www.fdanews.com/articles/197768-xpovio-approved-for-relapsedrefractory-diffuse-large-b-cell-lymphoma
Xpovio Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
June 24, 2020
The FDA has granted accelerated approval to Karyopharm Therapeutics’ Xpovio (selinexor) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
The approval was based on the results of a phase 2 clinical trial in which Xpovio demonstrated an overall response rate of 29 percent.
Xpovio had been granted priority review and fast-track designations.